ServiziMenu principaleHome

Peter van Dam

Peter van Dam
University Hospital Antwerp
Wilrijkstraat 10
2650 Edegem, BELGIUM


I became Head and Medical Coordinator Gynaecological Oncology and Senology division of the Antwerp University Hospital and was appointed professor at the Antwerp University. I am first and co-author of more than 250 peer reviewed publications and several book chapters (Scopus H-index 63) and am active in different national and international societies (eg ESMO, AACR, VVOG, EUSOMA). I was the first author of two recent papers of the EUSOMA task force on the effect of EUSOMA accreditation on the quality of breast cancer care in Europe. I was co-author of several multicentre international clinical trials on hormonal treatment of breast cancer. My present research interests are the effects of neoadjuvant treatment on the microenvironment in breast cancer, circulating tumour cells and cell free DNA in breast cancer patients and the biology and i mmune typing of inflammatory breast and cervical cancer. I am heavily involved in improving the quality of multidisciplinary breast cancer care in his hospital and Belgium and have published several papers and book chapters on this subject. I am a member of the editorial board of the European Journal of Surgical Oncology, and the International Journal of Molecular Sciences and am regularly asked to review papers for many other journals. As a member of the executive board of the European Society of Breast Cancer Specialists (EUSOMA) since 2020 I am heavily involved in the prevention, treatment of breast cancer on a European level , in close relation with policy makers. As I have more the 35 year experience in translational and clinical research in breast and gynaecological cancers, I feel I can contribute is the submitted project on several levels.

Most relevant papers

P. van Dam
Peeters, Marc; Van Dam, Peter André , Rasschaert, Marika Anna; Vulsteke, Christof; De Keersmaecker, Sven; Croes, Lieselot; Van Brussel, Ilse; Ravelingien, Jo; Janssens, Annelies; Prenen, Hans.
Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform.
ESMO OPEN - ISSN -5:3 (2020), p. - (c:irua:170785)

P. van Dam
Augustus, Elien; Van Casteren, Kaat; Sorber, Laure; Van Dam, Peter André , Roeyen, Geert; Peeters, Marc; Vorsters, Alex; Wouters, An; Raskin, Jo; Rolfo, Christian; Zwaenepoel, Karen; Pauwels, Patrick.
The art of obtaining a high yield of cell-free DNA from urine.
PLoS ONE - ISSN 1932-6203 - 15(2020), p. - (c:irua:170296)(IF tijdschrift: 2.74; jaar IF: 2019 )

P. van Dam
Rasschaert, Marika; Vulsteke, Christof; De Keersmaeker, Sven; Vandenborne, Kathleen; Dias, Stefanie; Verschaeve, Vincent; Vuylsteke, Peter; Van Brussel, Ilse; Ravelingien, Jo; Van Dam, Peter André , Segelov, Eva; Peeters, Marc. s.
AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patient
Supportive care in cancer - ISSN 0941-4355 - ( ), p.1-9 (c:irua:170202)(IF tijdschrift: 2.635; jaar IF: 2019; datum citaties: 16/08/2020)

P. van Dam
Augustus E, Van Casteren K, Sorber L, van Dam P, Roeyen G, Peeters M, Vorsters A, Wouters A, Raskin J, Rolfo C, Zwaenepoel K, Pauwels P.
The art of obtaining a high yield of cell-free DNA from urine.
PLoS One. 2020 Apr 6;15(4):e0231058. doi: 10.1371/journal.pone.0231058. PMID: 32251424; PMCID: PMC7135229

P. van Dam
Machiels M, Weytjens R, Erven K, Westerhoff JM, Amrouch S, Bosiers J, Verkinderen L, Hauspy J, van Dam P, Stevens P, Bernaerts A, Strijbos M, Meijnders P, Dirix P, Verellen D, Van Laere S, Vermeulen PB, Billiet C.
Oncological outcome, postoperative complications, and mammographic changes after intraoperative radiotherapy with electrons (IOERT) as a boost in a large single-institution cohort of breast cancer patients.
Breast J. 2020 Aug 11. doi: 10.1111/tbj.13986. Epub ahead of print. PMID: 32779870.

P. van Dam
Van Berckelaer C, Van Geyt M, Linders S, Rypens C, Trinh XB, Tjalma WAA, Van Laere S, Colpaert C, Dirix L, van Dam PA.
A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer.
Breast. 2020 Aug 17;53:212-220. doi: 10.1016/j.breast.2020.08.006. Epub ahead of print. PMID: 32890963.

P. van Dam
Bellens A, Roelant E, Sabbe B, Peeters M, van Dam PA.
A video-game based cognitive training for breast cancer survivors with cognitive impairment: A prospective randomized pilot trial.
Breast. 2020 Jun 12;53:23-32. doi: 10.1016/j.breast.2020.06.003. Epub ahead of print. PMID: 32554133; PMCID: PMC7375646.

P. van Dam
Oner G, Altintas S, Canturk Z, Tjalma W, Verhoeven Y, Van Berckelaer C, Berneman Z, Peeters M, Pauwels P, van Dam PA.
Triple-negative breast cancer-Role of immunology: A systemic review.
Breast J. 2020 May;26(5):995-999. doi: 10.1111/tbj.13696. Epub 2019 Dec 4. PMID: 31797488.

P. van Dam
Luyckx A, Wyckmans L, Bonte AS, Trinh XB, van Dam PA.
Acceptability of quality indicators for the management of endometrial, cervical and ovarian cancer: results of an online survey.
BMC Womens Health. 2020 Jul 23;20(1):151. doi: 10.1186/s12905-020-00999-3. PMID: 32703282; PMCID: PMC7376904.

P. van Dam
van Dam PA, Huizing M, Mestach G, Dierckxsens S, Tjalma W, Trinh XB, Papadimitriou K, Altintas S, Vermorken J, Vulsteke C, Janssens A, Berneman Z, Prenen H, Meuris L, Vanden Berghe W, Smits E, Peeters M.
SARS-CoV-2 and cancer: Are they really partners in crime?
Cancer Treat Rev. 2020 Sep;89:102068. doi: 10.1016/j.ctrv.2020.102068. Epub 2020 Jul 11. PMID: 32731090; PMCID: PMC7351667.

P. van Dam
Vermorken JB, van Dam P, Brand A
HIPEC in advanced epithelial ovarian cancer: why is there controversy? .
Curr Opin Oncol. 2020 Sep;32(5):451-458. doi: 10.1097/CCO.0000000000000659. PMID: 32675595.

P. van Dam
Verhoeven, Yannick; Tilborghs, Sam; Jacobs, Julie; De Waele, Jorrit; Quatannens, Delphine; Deben, Christophe; Prenen, Hans; Pauwels, Patrick; Trinh, Xuan Bich; Wouters, An; Smits, Evelien; Lardon, Filip; Van Dam, Peter André.
The potential and controversy of targeting STAT family members in cancer.
Seminars in cancer biology - ISSN 1044-579X - 60(2020), p.41-56. (c:irua:163320)(IF tijdschrift: 9.658; jaar IF: 2018)

P. van Dam
Rypens, Charlotte; Marsan, Melike; Van Berckelaer, Christophe; Billiet, Charlotte; Melis, Kirsten; Lopez, Sara Perez; Van Dam, Peter André , Devi, Gayathri R.; Finetti, Pascal; Ueno, Naoto T.; Bertucci, François; Dirix, Piet; Neven, Patrick; Vermeulen, Peter; Dirix, Luc; van Laere, Steven.
Inflammatory breast cancer cells are characterized by abrogated TGFß1-dependent cell motility and SMAD3 activity.
Breast cancer research and treatment - ISSN 0167-6806 - 180(2020), p.385-395. (c:irua:166286)(IF tijdschrift: 3.471; jaar IF: 2018)

P. van Dam
Dewulf, Jonatan; Vangestel, Christel; Verhoeven, Yannick; Van Dam, Peter André , Elvas, Filipe; van den Wyngaert, Tim; Clezardin, Philippe.
Bone metastases in the era of targeted treatments: insights from molecular biology. The quarterly journal of nuclear medecine and molecular imaging -
ISSN 1824-4785 - 63(2019), p.98-111. (c:irua:162912)(IF tijdschrift: 1.931; jaar IF: 2018; datum citaties: 19/03/2020).

P. van Dam
Aronson SL, Lopez-Yurda M, Koole SN, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van Gent MDJM, Arts HJG, van Ham MAPC, van Dam PA, Vuylsteke P, Aalbers AGJ, Verwaal VJ, Van de Vijver KK, Aaronson NK, Sonke GS, van Driel WJ.
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
Lancet Oncol. 2023 Oct;24(10):1109-1118. doi: 10.1016/S1470-2045(23)00396-0. Epub 2023 Sep 11.PMID: 37708912

P. van Dam
Oner G, Broeckx G, Van Berckelaer C, Zwaenepoel K, Altintas S, Canturk Z, Tjalma W, Berneman Z, Peeters M, Pauwels P, van Dam PA.
The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy.
Cancer Med. 2023 Sep;12(17):17901-17913. doi: 10.1002/cam4.6425. Epub 2023 Aug 8.PMID: 37553911

P. van Dam
Debie Y, van Dam PA, Goossens ME, Peeters M, Vandamme T.
Boosting capacity of a fourth dose BNT162b2 in cancer patients.
Eur J Cancer. 2023 Jan;179:121-123. doi: 10.1016/j.ejca.2022.11.016. Epub 2022 Nov 24.PMID: 36521333

P. van Dam
Debie Y, Van Audenaerde JRM, Vandamme T, Croes L, Teuwen LA, Verbruggen L, Vanhoutte G, Marcq E, Verheggen L, Le Blon D, Peeters B, Goossens ME, Pannus P, Ariën KK, Anguille S, Janssens A, Prenen H, Smits ELJ, Vulsteke C, Lion E, Peeters M, van Dam PA.
Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.
Clin Cancer Res. 2023 Feb 1;29(3):635-646. doi: 10.1158/1078-0432.CCR-22-2185.PMID: 36341493

P. van Dam
De Jaeghere EA, Tuyaerts S, Van Nuffel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Denys HG.
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.
Cancer Immunol Immunother. 2023 Feb;72(2):475-491. doi: 10.1007/s00262-022-03253-x. Epub 2022 Aug 12.PMID: 35960332

P. van Dam
Dewulf J, Hrynchak I, Geudens S, Pintelon I, Vangestel C, Sereno J, van Dam PA, Abrunhosa AJ, Elvas F, Van den Wyngaert T.
Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments.
Pharmaceutics. 2022 Apr 26;14(5):939. doi: 10.3390/pharmaceutics14050939.PMID: 35631525

P. van Dam
Debie Y, Vandamme T, Goossens ME, van Dam PA, Peeters M.
Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer.
Eur J Cancer. 2022 Mar;163:177-179. doi: 10.1016/j.ejca.2021.12.025. Epub 2021 Dec 29.PMID: 35077960

P. van Dam
De Winter FHR, Hotterbeekx A, Huizing MT, Konnova A, Fransen E, Jongers B, Jairam RK, Van Averbeke V, Moons P, Roelant E, Le Blon D, Vanden Berghe W, Janssens A, Lybaert W, Croes L, Vulsteke C, Malhotra-Kumar S, Goossens H, Berneman Z, Peeters M, van Dam PA, Kumar-Singh S.
Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients.
Cancers (Basel). 2021 Nov 15;13(22):5718. doi: 10.3390/cancers13225718.PMID: 34830872

P. van Dam
Van Berckelaer C, Vermeiren I, Vercauteren L, Rypens C, Oner G, Trinh XB, Tjalma WAA, Broeckx G, Charafe-Jauffret E, Van Laere S, Bertucci F, Colpaert C, van Dam PA.
The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Cancers (Basel). 2021 Sep 16;13(18):4656. doi: 10.3390/cancers13184656.PMID: 34572883

P. van Dam
Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, Harbeck N, Lüftner D, Rottey S, van Dam PA, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen VCG, Cortes J, Locci M, Paris I, Del Mastro L, De Placido S, Martín M, Jerusalem G, Venturini S, Curigliano G, Generali D.
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer.
Cancers (Basel). 2021 Sep 1;13(17):4421. doi: 10.3390/cancers13174421.PMID: 34503231